株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaSphere:新興のバイオテクノロジー - 幹細胞治療

PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy

発行 GlobalData 商品コード 318758
出版日 ページ情報 英文 248 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
PharmaSphere:新興のバイオテクノロジー - 幹細胞治療 PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy
出版日: 2014年11月10日 ページ情報: 英文 248 Pages
概要

当レポートでは、世界の幹細胞産業について調査分析し、主要な開発動向、規制の要件、最近の取引活動、業界動向、主要企業の経営戦略のほか、地域別市場の分析、規制の枠組み、パイプライン、戦略的見通しなどについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 幹細胞の概要

  • 定義
  • 幹細胞の種類
  • 幹細胞の研究タイムライン
  • 治療への応用
  • 知的財産(IP)

第4章 幹細胞のパイプライン

  • 開発段階
  • 治療分野
  • 適応症
  • プラットフォーム技術の譲渡
  • 幹細胞の主要パイプライン

第5章 幹細胞の臨床試験

  • 臨床試験の概要
  • 開発の段階
  • 治験の状況
  • 治療分野
  • 適応症
  • 地域
  • スポンサー
  • 治験責任医師

第6章 幹細胞関連の取引

  • 年間動向
  • 取引の種類
  • 地域
  • 治療分野
  • M&A
  • 資産取引
  • ライセンス契約
  • パートナーシップ
  • 資本調達
  • 主要な取引

第7章 幹細胞に対する規制

  • イントロダクション
  • 米国
  • 欧州
  • 日本
  • インド
  • 韓国
  • 中国
  • イスラエル

第8章 企業情勢

  • 組織別
  • 地域別
  • 企業分析
  • 企業の財務分析

第9章 戦略的見通し

  • 幹細胞産業の課題
  • 幹細胞市場の機会

第10章 付録

図表

目次
Product Code: GDHC012PSR

GlobalData's report "PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy", provides strategic analysis of the global stem cells industry. It discusses key development trends, regulatory requirements in various markets, recent deals activity and industry dynamic trends, as well as describes the operations strategy of these companies. Furthermore, it includes a geographical segmentation of various markets including the EU and US, as well as emerging markets such as China, India, SouthKorea, and Israel-providing in-depth analysis of these markets' regulatory framework, key domestic players and their stem cell pipelines, and strategic outlook.

Throughout the report, GlobalData's analysts provide you with expert insight, expanding on each strategy and factor discussed, with the aim of providing you with the tools needed for making informed business decisions.

Highlights

Key Questions Answered

  • (Q.) What are the key market drivers of the global stem cell industry
  • (Q.) Who are the top players involved in the development of stem cell therapies in developed as well as developing countries
  • (Q.) What are the main regulatory measures affecting the stem cell industry in the US, Europe, Japan, India, South Korea, China and Israel
  • (Q.) What are the major trends in stem cell clinical trials and profiles of key investigators
  • (Q.) What specific strategies are companies utilizing to combat some of the challenges currently facing the development of therapies in the global stem cell industry

Scope

  • Stem Cell Market Dynamics: This report provides analysis of the key drivers and trends shaping the global Stem Cell therapy market, including manufacturing, emerging markets, and development pipeline.
  • Financial Performance Insight: Report uses GlobalData's proprietary data across 22 key financial metrics to provide insight over stem cell company performance.
  • PipelineAnalysis: Detailed information on ten leading stem cell therapies; trend analysis of clinical trial studies and investigators covering over 1000 trials related to stem cell therapies.
  • Deal strategies: Exhaustive discussion on the strategic implications and synergies of deals including, M&A, collaboration as well as capital raisings such as equity offerings, private equity and venture financing activities.
  • Regulatory Implications: Guidelines for stem cell usage for developing therapies in seven major markets for stem cells including US, Europe, Japan, SouthKorea, Israel, China and India.
  • Company Analysis: Company landscape covering 40 companies on full pipeline, financials and key overview information.

Reasons to buy

  • Identify the key domestic players in various stem cell markets, including South Korea, Japan and emerging markets such as India and China.
  • Understand the key drivers and trends in the global stem cell industry.
  • Analyze and track the strategies that companies are using to enter and/or strengthen their position in the evolving stem cell industry, as well as efforts being made by innovator companies like Pfizer and Novartis to enter this market.
  • Use this information as an independent source for your due diligence and transaction strategy.
  • Understand the regulatory framework and be prepared to tackle challenges facing the stem cell based therapies.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Report Scope
  • 2.2. Upcoming Related Reports
  • 2.3. Recently Published Reports

3. Stem Cell Overview

  • 3.1. Definition
    • 3.1.1. Renewal
    • 3.1.2. Potency
  • 3.2. Types of Stem Cell
    • 3.2.1. Embryonic Stem Cells
    • 3.2.2. Adult Stem Cells
    • 3.2.3. Induced Pluripotent Stem Cells
    • 3.2.4. Cord-Blood-Derived Stem Cells
    • 3.2.5. Amniotic Stem Cells
    • 3.2.6. Fetal Stem Cells
  • 3.3. Stem Cell Research Timeline
  • 3.4. Therapeutic Applications
    • 3.4.1. Cardiovascular
    • 3.4.2. Central Nervous System
    • 3.4.3. Diabetes
    • 3.4.4. Oncology
    • 3.4.5. Ophthalmology
    • 3.4.6. Musculoskeletal Disorders
  • 3.5. Intellectual Property
    • 3.5.1. United States
    • 3.5.2. Europe
    • 3.5.3. Japan

4. Stem Cell Pipeline

  • 4.1. Development Stages
  • 4.2. Therapy Areas
  • 4.3. Indications
  • 4.4. Platform Technology Transfers
    • 4.4.1. Types of Stem Cell Platform Technologies
    • 4.4.2. Partnerships Between Universities and Companies
  • 4.5. Stem Cell Pipeline in Focus
    • 4.5.1. Prochymal (Mesoblast)
    • 4.5.2. Adult Autologous CD34+ Stem Cells (Baxter)
    • 4.5.3. StemEx (Gamida Cell)
    • 4.5.4. Allogeneic MPC for Bone Marrow Transplantation (Mesoblast)
    • 4.5.5. Preob (Bone Therapeutics)
    • 4.5.6. Cerecellgram (Pharmicell)
    • 4.5.7. Revascor or CEP-41750 (Mesoblast)
    • 4.5.8. Tumor Stem Cell Specific Dendritic Cell Therapy (Neostem Oncology)
    • 4.5.9. GSK-2696273 (GlaxoSmithKline)
    • 4.5.10. Lenti-D (Bluebird bio)

5. Stem Cell Clinical Trials

  • 5.1. Clinical Trial Overview
  • 5.2. Stages of Development
  • 5.3. Trial Status
  • 5.4. Therapy Area
  • 5.5. Indication
  • 5.6. Geography
  • 5.7. Sponsors
  • 5.8. Investigators
    • 5.8.1. Specialty
    • 5.8.2. Geography
    • 5.8.3. Designation
    • 5.8.4. Associated Organizations

6. Stem Cell Deals

  • 6.1. Annual Trends
  • 6.2. Deal Types
    • 6.2.1. Average Deal Value
    • 6.2.2. Deal Structure
  • 6.3. Regions
  • 6.4. Therapy Areas
  • 6.5. Mergers & Acquisitions
    • 6.5.1. M&A Deals by Region
  • 6.6. Asset Transactions
  • 6.7. Licensing Agreements
    • 6.7.1. Licensing Agreements by Therapy Area
  • 6.8. Partnerships
  • 6.9. Capital Raisings
    • 6.9.1. Equity Offerings
    • 6.9.2. Private Equity
    • 6.9.3. Venture Financing
  • 6.10. Highlighted Deals
    • 6.10.1. Mergers and Acquisitions
    • 6.10.2. Licensing Agreements
    • 6.10.3. Partnerships
    • 6.10.4. Venture Financing

7. Stem Cell Regulation

  • 7.1. Introduction
  • 7.2. US
    • 7.2.1. Overview
    • 7.2.2. Regulatory Framework
    • 7.2.3. Key Players
  • 7.3. Europe
    • 7.3.1. Overview
    • 7.3.2. Regulatory Framework
    • 7.3.3. Key Players
  • 7.4. Japan
    • 7.4.1. Overview
    • 7.4.2. Regulatory Framework
    • 7.4.3. Key Players
  • 7.5. India
    • 7.5.1. Overview
    • 7.5.2. Regulatory Framework
    • 7.5.3. Key Players
  • 7.6. South Korea
    • 7.6.1. Overview
    • 7.6.2. Regulatory Framework
    • 7.6.3. Key Players
  • 7.7. China
    • 7.7.1. Overview
    • 7.7.2. Regulatory Framework
    • 7.7.3. Key Players
  • 7.8. Israel
    • 7.8.1. Overview
    • 7.8.2. Regulatory Framework
    • 7.8.3. Key Players

8. Company Landscape

  • 8.1. Organizational Split
  • 8.2. Geographical Split
  • 8.3. Company Analysis
    • 8.3.1. Pharmicell
    • 8.3.2. Mesoblast
    • 8.3.3. Pluristem
    • 8.3.4. NeoStem
    • 8.3.5. Celgene
    • 8.3.6. Cellerant Therapeutics
    • 8.3.7. Cellular Biomedicine Group
    • 8.3.8. K-Stemcell
    • 8.3.9. Anterogen
    • 8.3.10. Asterias Biotherapeutics
    • 8.3.11. MediPost
    • 8.3.12. Reliance Life Sciences
    • 8.3.13. Stempeutics
    • 8.3.14. Advanced Cell Technology
    • 8.3.15. Athersys
    • 8.3.16. Escape Therapeutics
    • 8.3.17. Orbsen Therapeutics
    • 8.3.18. Shenzhen Beike Biotechnology
    • 8.3.19. StemCells
    • 8.3.20. Bioheart
    • 8.3.21. CHA Bio & Diostech
    • 8.3.22. Cytomedix
    • 8.3.23. Fate Therapeutics
    • 8.3.24. Hygieia Innovation
    • 8.3.25. Medistem
    • 8.3.26. Neuralstem
    • 8.3.27. Kasiak Research
    • 8.3.28. ReNeuron
    • 8.3.29. TiGenix NV
    • 8.3.30. California Stem Cell
    • 8.3.31. Capricor Therapeutics
    • 8.3.32. Gamida Cell
    • 8.3.33. Histocell
    • 8.3.34. Bone Therapeutics
    • 8.3.35. Cardio3 BioSciences
    • 8.3.36. Promethera Biosciences
    • 8.3.37. Stemedica
    • 8.3.38. Tulane University
    • 8.3.39. BrainStorm Cell Therapeutics
    • 8.3.40. Cell Cure Neurosciences
  • 8.4. Financial Analysis of Companies
    • 8.4.1. Total Revenue
    • 8.4.2. Cost of Revenue
    • 8.4.3. Gross Profit
    • 8.4.4. Selling, General, and Administrative Expenses
    • 8.4.5. Research & Development
    • 8.4.6. Total Operating Expense
    • 8.4.7. Operating Income
    • 8.4.8. Provision for Taxes
    • 8.4.9. Net Income
    • 8.4.10. Cash and Short-Term Investments
    • 8.4.11. Net Property/Plants/Equipment
    • 8.4.12. Long-Term Investments
    • 8.4.13. Long-Term Debt
    • 8.4.14. Total Debt
    • 8.4.15. Debt-to-Equity Ratio
    • 8.4.16. Cash Ratio
    • 8.4.17. Market Capitalization

9. Strategic Outlook

  • 9.1. Stem Cell Industry Challenges
    • 9.1.1. Complicated Manufacturing Process
    • 9.1.2. High Cost of Research, Production, and Commercialization
    • 9.1.3. Untested Regulatory Pathways
    • 9.1.4. Undercapitalized Sector
  • 9.2. Stem Cell Market Opportunities
    • 9.2.1. Discovery of Therapeutic Candidates
    • 9.2.2. Promising Rise of Adult Stem Cells
    • 9.2.3. Clinical Trial Outcomes Will Accelerate Deal-Making Opportunities

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
    • 10.3.1. Coverage
    • 10.3.2. Secondary Research
    • 10.3.3. Expert Panel Validation
  • 10.4. About the Authors
    • 10.4.1. Analyst
    • 10.4.2. Director of Healthcare Industry Dynamics
    • 10.4.3. Global Head of Healthcare
  • 10.5. About the Industry Dynamics Team
  • 10.6. About GlobalData
  • 10.7. Disclaimer

List of Tables

  • Table 1: Milestones in Stem Cell Research
  • Table 2: Platform Technologies Adopted from Academic Institutions
  • Table 3: Prochymal
  • Table 4: Adult Autologous CD34+ Stem Cells
  • Table 5: StemEx
  • Table 6: Allogeneic MPC For Bone Marrow Transplantation
  • Table 7: Preob
  • Table 8: Cerecellgram
  • Table 9: Revascor
  • Table 10: Tumor Stem Cell Specific Dendritic Cell Therapy
  • Table 11: GSK-2696273
  • Table 12: Lenti-D (Bluebird bio)
  • Table 13: Highlighted M&A Deals, January 1, 2004-March 1, 2014
  • Table 14: Top 10 Stem Cell Licensing Agreement Deals, January 1 2004-March 1, 2014
  • Table 15: Top 10 Stem Cell Partnership Deals, January 1, 2004-March 1, 2014
  • Table 16: Top 10 Stem Cell Partnership Deals, 2004-2014
  • Table 17: Countries with Embyronic Stem Cell Policies
  • Table 18: Main Measures included in the HHS Guidelines on the use of hESCs and iPSCs.
  • Table 19: Main Measures included in the Ethical Guidelines for Biomedical Research on Human Participants
  • Table 20: Pharmicell Company Overview
  • Table 21: Pharmicell Stem Cell Product Pipeline
  • Table 22: Pharmicell Key Financials, 2011-2013 ($m)
  • Table 23: Mesoblast Company Overview
  • Table 24: Mesoblast Stem Cell Pipeline
  • Table 25: Mesoblast Key Financials, 2011-2013 ($m)
  • Table 26: Pluristem Company Overview
  • Table 27: Pluristem Therapeutics Inc. Stem Cell Pipeline
  • Table 28: Pluristem Key Financials, 2011-2013 ($m)
  • Table 29: NeoStem Company Overview
  • Table 30: NeoStem Stem Cell Pipeline
  • Table 31: NeoStem Inc. Key Financials, 2011-2013 ($m)
  • Table 32: Celgene Company Overview
  • Table 33: Celgene Stem Cell Pipeline
  • Table 34: Celgene Key Financials, 2011-2013 ($m)
  • Table 35: Cellerant Therapeutics Company Overview
  • Table 36: Cellerant Stem Cell Pipeline
  • Table 37: Cellular Biomedicine Group Company Overview
  • Table 38: Cellular Biomedicine Group Stem Cell Pipeline
  • Table 39: Cellular Biomedicine Group. Key Financials, 2011-2013 ($m)
  • Table 40: K-Stemcell Company Overview
  • Table 41: K-Stemcell Stem Cell Pipeline
  • Table 42: Anterogen Company Overview
  • Table 43: Anterogen Stem Cell Pipeline
  • Table 44: Asterias Biotherapeutics Company Overview
  • Table 45: Asterias Biotherapeutics Stem Cell Pipeline
  • Table 46: MediPost Company Overview
  • Table 47: MediPost Stem Cell Pipeline
  • Table 48: MediPost Key Financials, 2011-2013 ($m)
  • Table 49: Reliance Life Sciences Company Overview
  • Table 50: Reliance Life Sciences Stem Cell Pipeline
  • Table 51: Stempeutics Company Overview
  • Table 52: Stempeutics Stem Cell Pipeline
  • Table 53: Advanced Cell Technology Company Overview
  • Table 54: Advanced Cell Technology Stem Cell Pipeline
  • Table 55: Advanced Cell Technology Inc. Key Financials, 2011-2013 ($m)
  • Table 56: Athersys Company Overview
  • Table 57: Athersys Stem Cell Pipeline
  • Table 58: Athersys Key Financials, 2011-2013 ($m)
  • Table 59: Escape Therapeutics Company Overview
  • Table 60: Escape Therapeutics Stem Cell Pipeline
  • Table 61: Orbsen Therapeutics Company Overview
  • Table 62: Orbsen Therapeutics Stem Cell Pipeline
  • Table 63: Shenzhen Beike Biotechnology Company Overview
  • Table 64: Shenzhen Beike Biotechnology Stem Cell Pipeline
  • Table 65: StemCells Company Overview
  • Table 66: StemCells Stem Cell Pipeline
  • Table 67: Stempeutics Key Financials, 2011-2013 ($m)
  • Table 68: Bioheart Company Overview
  • Table 69: Bioheart Stem Cell Pipeline
  • Table 70: Bioheart Key Financials, 2011-2013 ($m)
  • Table 71: CHA Bio & Diostech Company Overview
  • Table 72: CHA Bio & Diostech Co., Ltd Stem Cell Pipeline
  • Table 73: CHA Bio & Diostech Key Financials, 2011-2013 ($m)
  • Table 74: Cytomedix Company Overview
  • Table 75: Cytomedix Stem Cell Pipeline
  • Table 76: CytomedixKey Financials, 2011-2013 ($m)
  • Table 77: Fate Therapeutics
  • Table 78: Fate Therapeutics Stem Cell Pipeline
  • Table 79: Fate Therapeutics Key Financials, 2011-2013 ($m)
  • Table 80: Hygieia Innovation Company Overview
  • Table 81: Hygieia Innovation Stem Cell Pipeline
  • Table 82: Medistem Company Overview
  • Table 83: MedistemStem Cell Pipeline
  • Table 84: Neuralstem Company Overview
  • Table 85: Neuralstem Stem Cell Pipeline
  • Table 86: Neuralstem Key Financials, 2011-2013 ($m)
  • Table 87: Kasiak Research Company Overview
  • Table 88: Kasiak Research Stem Cell Pipeline
  • Table 89: ReNeuron Company Overview
  • Table 90: ReNeuron Stem Cell Pipeline
  • Table 91: ReNeuron Group Key Financials, 2011-2013 ($m)
  • Table 92: TiGenix NV
  • Table 93: TiGenix Stem Cell Pipeline
  • Table 94: TiGenix NV Key Financials, 2011-2013 ($m)
  • Table 95: California Stem Cell Company Overview
  • Table 96: California Stem Cell Stem Cell Pipeline
  • Table 97: Capricor Therapeutics
  • Table 98: Capricor Stem Cell Pipeline
  • Table 99: Capricor Therapeutics Inc. Key Financials, 2011-2013 ($m)
  • Table 100: Gamida Cell Company Overview
  • Table 101: Gamida Cell Stem Cell Pipeline
  • Table 102: Histocell Company Overview
  • Table 103: Histocell Stem Cell Pipeline
  • Table 104: Bone Therapeutics
  • Table 105: Bone Therapeutics SA Stem Cell Pipeline
  • Table 106: Cardio3 BioSciences
  • Table 107: Cardio3 BioSciences Stem Cell Pipeline
  • Table 108: Cardio3 BioSciences Key Financials, 2011-2013 ($m)
  • Table 109: Promethra BioSciences
  • Table 110: Promethra BioSciences Stem Cell Pipeline
  • Table 111: Stemedica Company Overview
  • Table 112: Stemedica Stem Cell Pipeline
  • Table 113: Tulane University
  • Table 114: Tulane University Stem Cell Pipeline
  • Table 115: BrainStorm Cell Therapeutics
  • Table 116: BrainStorm Cell Therapeutics Stem Cell Pipeline
  • Table 117: Cellerant Therapeutics Key Financials, 2011-2013 ($m)
  • Table 118: Cell Cure Neurosciences Company Overview
  • Table 119: Cell Cure Neurosciences Stem Cell Pipeline
  • Table 120: Estimated Cost of manufacturing 2500 doses of autologous & allogeneic stem cell therapies

List of Figures

  • Figure 1: Number of Unique Stem Cell Therapies Per Company
  • Figure 2: Number of Stem Cell Therapy Indications Per Company (Top 27)
  • Figure 3: Stem Cell Therapy Programs by Stage of Development
  • Figure 4: Stem Cell Pipeline by Therapy Area
  • Figure 5: Stem Cell Pipeline By Indication (Top 31)
  • Figure 6: Stem Cell Pipeline by Number of Indications Under Investigation
  • Figure 7: Stem Cell Clinical Trials Annual Trend, 2004-2014
  • Figure 8: Stem Cell Clinical Trials by Phase of Development, 2004-March 1, 2014
  • Figure 9: Stem Cell Clinical Trials by Status, January 1, 2004-March 1, 2014
  • Figure 10: Stem Cell Clinical Trials by Therapy Area, January 1, 2004-March 1, 2014
  • Figure 11: Stem Cell Clinical Trials Top 20 Indications, January 1, 2004-March 1, 2014
  • Figure 12: Stem Cell Clinical Trials Top 15 Countries, January 1, 2004-March 1, 2014
  • Figure 13: Top Stem Cell Clinical Trial Sponsors, January 1, 2004-March 1, 2014
  • Figure 14: Stem Cell Investigator Specialties, January 1, 2004- March 1, 2014
  • Figure 15: Countries Ranked by Number of Stem Cell Trial Investigators, 2004-2014
  • Figure 16: Designations of Stem Cell Trial Investigators, January 1, 2004 - March 1, 2014
  • Figure 17: Leading Organizations Associated with Stem Cell Trial Investigators, January 1, 2004 - March 1, 2014
  • Figure 18: Stem Cell Deal Volume and Value Trends, 2004-2013
  • Figure 19: Stem Cell Deal Volume and Value by Type, January 1, 2004-March 1, 2014
  • Figure 20: Average Deal Value in the Stem Cell Sector, January 1, 2004-March 1, 2014
  • Figure 21: Stem Cell Partnership and Licensing Agreement Deal Structure, January 1, 2004-March 1, 2014
  • Figure 22: Stem Cell Deal Volume and Value by Region, January 1, 2004-March 1, 2014
  • Figure 23: Stem Cell Deal Volume and Value by Therapy Area, January 1, 2004-March 1, 2014
  • Figure 24: M&A Deal Volume and Value, January 1, 2004-March 1, 2014
  • Figure 25: Stem Cell M&A Deal Volume by Country, January 1, 2004-March 1, 2014
  • Figure 26: Stem Cell Asset Transaction Volume and Value, 2004-2013
  • Figure 27: Licensing Agreement Volume and Value, 2004-2013
  • Figure 28: Licensing Agreements by Therapy Area, January 1, 2004-March 1, 2014
  • Figure 29: Partnership Deal Volume and Value, 2004-2013
  • Figure 30: Equity Offering Volume and Value, 2004-2013
  • Figure 31: Venture Financing Deal Volume and Value, 2004-2013
  • Figure 32: Organizational Split Across the Stem Cell Industry
  • Figure 33: Regional Split of Stem Cell Company Headquarters
  • Figure 34: Distribution of Stem Cell Companies, by Country
  • Figure 35: Total Revenue of Public Stem Cell Companies (2013, $m)
  • Figure 36: Cost of Revenue of Public Stem Cell Companies (2013, $m)
  • Figure 37: Gross Profit of Public Stem Cell Companies (2013, $m)
  • Figure 38: SGA Expenses of Public Stem Cell Companies (2013, $m)
  • Figure 39: R&D Expenses of Public Stem Cell Companies (2013, $m)
  • Figure 40: Total Operating Expenses of Public Stem Cell Companies (2013, $m)
  • Figure 41: Operating Income of Public Stem Cell Companies (2013, $m)
  • Figure 42: Provision For Taxes of Public Stem Cell Companies (2013, $m)
  • Figure 43: Net Income of Public Stem Cell Companies (2013, $m)
  • Figure 44: Cash and Short-Term Investments of Public Stem Cell Companies (2013, $m)
  • Figure 45: Net Property/Plant/Equipment Spending of Public Stem Cell Companies (2013, $m)
  • Figure 46: Long Term Investments of Public Stem Cell Companies (2013, $m)
  • Figure 47: Long Term Debt of Public Stem Cell Companies (2013, $m)
  • Figure 48: Total Debt of Public Stem Cell Companies (2013, $m)
  • Figure 49: Debt-to-Equity Ratios of Public Stem Cell Companies (2013)
  • Figure 50: Cash Ratio of Public Stem Cell Companies (2013)
  • Figure 51: Market Capitalization of Public Stem Cell Companies (2013, $m)
Back to Top